PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

20180129 155949
20180131 184159
20180815 152156
20170804 165409
20170730 173527
IMG-20170806-WA0045
  • Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 25, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 25, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 15, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • Q1 Stability Testing of Drug Substances and Drug Products
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-23 By FDA
  • Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Date of authorisation: 20/02/2014, Revision: 24, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • Human medicines European public assessment report (EPAR): Grepid, clopidogrel, Date of authorisation: 27/07/2009, Revision: 29, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • Human medicines European public assessment report (EPAR): Nustendi, bempedoic acid,ezetimibe, Date of authorisation: 27/03/2020, Revision: 8, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • Human medicines European public assessment report (EPAR): Nilemdo, bempedoic acid, Date of authorisation: 01/04/2020, Revision: 9, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • October 10, 2024: Meeting of the Cardiovascular and Renal Drugs Advisory Committee - 10/10/2024
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-21 By FDA
  • User Fee Lists
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-21 By FDA
  • Counterfeit Medicine
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-20 By FDA
  • PREA Non-Compliance Letters
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-06-20 By FDA
  • Internet Pharmacy Warning Letters
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-20 By FDA
  • DG Gel Card 125445, 125449, 125450 - 125457
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-06-20 By FDA
  • Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine,tozinameran,riltozinameran and tozinameran,famtozinameran and tozinameran,raxtozinameran, Date of authorisation: 21/12/2020, Revision: 54, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-20
Older posts
Theme: Scaffold by Danny Cooper.